Earnings summaries and quarterly performance for VYNE Therapeutics.
Executive leadership at VYNE Therapeutics.
Board of directors at VYNE Therapeutics.
Research analysts who have asked questions during VYNE Therapeutics earnings calls.
CL
Carvey Leung
Cantor Fitzgerald
4 questions for VYNE
Also covers: ONCY, SCYX, THTX
David Amsellem
Piper Sandler Companies
4 questions for VYNE
Also covers: ABBV, ALKS, AMGN +27 more
Patrick Dolezal
LifeSci Capital
4 questions for VYNE
Also covers: ADVM, LRMR, RCKT
KC
Ken Cacciatore
Cowen & Company
2 questions for VYNE
Also covers: BHVN
OL
Oren Livnat
H.C. Wainwright
2 questions for VYNE
Also covers: ANIP, AVDL, CARA +7 more
BP
Balaji Prasad
Barclays
1 question for VYNE
Also covers: ALVO, AMRX, ELAN +7 more
Recent press releases and 8-K filings for VYNE.
VYNE Therapeutics Amends Merger Agreement with Yarrow Bioscience
VYNE
M&A
Convertible Preferred Issuance
Dividends
- VYNE Therapeutics Inc. entered into Amendment No. 1 to its Agreement and Plan of Merger and Reorganization with Yarrow Bioscience, Inc. on January 30, 2026, for an agreement originally dated December 17, 2025.
- The amendment introduces Pre-Funded Warrants that VYNE may issue to holders of Yarrow capital stock if their share entitlement in the merger exceeds a beneficial ownership limitation. These warrants allow the holder to purchase VYNE Common Stock equal to the "Remaining Entitlement".
- The Beneficial Ownership Limitation can be designated by each holder between 0% and 19.99% of the Parent Common Stock outstanding post-merger, defaulting to 9.99% if no designation is made.
- The amendment also clarifies that the Parent Pre-Closing Dividend may be awarded to holders of outstanding VYNE Common Stock and shares underlying certain outstanding VYNE warrants.
7 days ago
VYNE Therapeutics Announces Merger with Yarrow Bioscience
VYNE
M&A
CEO Change
New Projects/Investments
- VYNE Therapeutics has entered into an all-stock merger agreement with privately held Yarrow Bioscience.
- Pre-merger VYNE stockholders are expected to own approximately 3% of the combined company and will receive a cash dividend of approximately $14.5-$16.5 million.
- The combined entity, to be named Yarrow Bioscience Incorporated and trading under YARW on Nasdaq, will focus on developing YB-101 for Graves' disease and Thyroid Eye Disease.
- The merger is anticipated to close in the second quarter of 2026, with the combined company expected to have a cash runway into 2028, bolstered by $200 million from pre-closing private placements.
- Dr. Rebecca Frey, current CEO of Yarrow, is slated to become the CEO of the combined company.
Dec 17, 2025, 1:30 PM
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
VYNE
M&A
Dividends
New Projects/Investments
- VYNE Therapeutics and Yarrow Bioscience have entered into an all-stock merger agreement, with the combined entity to be named Yarrow Bioscience Incorporated and trade under the ticker YARW on NASDAQ.
- Pre-merger VYNE stockholders are expected to own approximately 3% of the combined company and will receive a cash dividend of approximately $14.5-$16.5 million.
- The combined company is anticipated to have a cash runway into 2028, bolstered by $200 million from pre-closing private placements, to advance its lead asset, YB101, for Graves' disease and thyroid eye disease.
- The transaction is expected to close in the second quarter of 2026.
Dec 17, 2025, 1:30 PM
VYNE Therapeutics and Yarrow Bioscience Announce All-Stock Merger
VYNE
M&A
Dividends
New Projects/Investments
- VYNE Therapeutics and Yarrow Bioscience have entered into an all-stock merger agreement, with the combined company focusing on Yarrow's lead asset, YB101, for Graves' disease and thyroid eye disease (TED).
- Pre-merger VYNE stockholders are expected to own approximately 3% of the combined company and receive a cash dividend of approximately $14.5-$16.5 million immediately prior to closing.
- The combined company is projected to have a cash runway into 2028, supported by $200 million from pre-closing private placements in Yarrow by leading biotech investors.
- The merger is expected to close in the second quarter of 2026, after which the combined entity will operate as Yarrow Bioscience Incorporated and trade under the ticker YARW.
- Yarrow intends to initiate a combined Phase 1B/2B trial of YB101 in Graves' disease in the United States and other territories in the first half of 2026.
Dec 17, 2025, 1:30 PM
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
VYNE
M&A
- VYNE Therapeutics Inc. and Yarrow Bioscience, Inc. entered into an Agreement and Plan of Merger and Reorganization on December 17, 2025.
- The "Company Equity Value" for Yarrow Bioscience, Inc. is defined as $30,000,000.
- A joint press release was issued, and a conference call was scheduled for December 17, 2025, to discuss the merger.
- The combined company is expected to be listed on Nasdaq after the closing of the proposed merger.
Dec 17, 2025, 1:15 PM
VYNE Therapeutics Inc. Reports Q3 2025 Financial Results and Business Update
VYNE
Earnings
Guidance Update
New Projects/Investments
- VYNE Therapeutics reported revenues of $0.2 million for the three months ended September 30, 2025, with a net loss of $7.3 million and a net loss per share of $0.17.
- As of September 30, 2025, the company had $32.7 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the first half of 2027 based on current operating assumptions and cost reductions.
- VYNE is conducting an ongoing strategic review to evaluate options for maximizing shareholder value, including internal pipeline opportunities and broader strategic alternatives.
- A 12-week non-clinical toxicology study of VYN202 in dogs is in progress to address a partial clinical hold for male subjects, while the Phase 2b trial for repibresib gel has been terminated following topline results.
Nov 6, 2025, 1:02 PM
Quarterly earnings call transcripts for VYNE Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more